高级检索
当前位置: 首页 > 详情页

Activated PI3K/Akt/COX-2 Pathway Induces Resistance to Radiation in Human Cervical Cancer HeLa Cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Dept Oncol, Tong Ji Hosp, TongJi Med Coll, Wuhan 430030, Peoples R China [2]Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Union Hosp, TongJi Med Coll, Wuhan 430030, Peoples R China
出处:
ISSN:

关键词: cervical cancer COX-2 PI3K/Akt radiation resistance

摘要:
Activation of Akt, or protein kinase B, is frequently observed in human cancers. It has been demonstrated that PI3K activation leads to radiation resistance. Here, the role of PI3K/Akt/COX-2 pathway in the resistance to radiation in human cervical cancer HeLa cells is explored. Cultured HeLa cells were randomly assigned to five treatment groups: control, radiation, LY294002, PI3K antagonist, and the COX-2-antagonist celecoxib, with the objective of determining the role of PI3K/Akt/COX-2 pathway in the radiation resistance of HeLa cells. The cell survival ratios were computed by clone formation. To calculate the quasi-threshold dose (Dq), mean lethal dose (D(0)), survival fraction at 2 Gy radiation dose (SF(2)), and radiosensitization ratio, the cell survival curves were fitted to the one-hit multitarget model. The protein expression profiles for pAkt, Akt, COX-2, Bad, and pBad were detected by Western blot analysis, and the mRNA expression profiles for COX-2 and Bad were analyzed by RT-polymerase chain reaction. Treatment with a combination of celecoxib, LY294002, and radiation resulted in elevated Dq, D(0), and SF(2), and increased radiosensitivity in HeLa cells. The PI3K/Akt/COX-2 pathway was activated by radiation, whereas celecoxib inhibited the activation of the PI3K/Akt/COX-2 axis through several targets. Our results indicate that the activated PI3K/Akt/COX-2 signal transduction pathway was the main cause for decline in radiosensitivity in HeLa cells. This study proposes that the inhibition of the PI3K/Akt/COX-2 pathway can synergistically enhance radiation efficacy.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2009]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学 4 区 药学 4 区 核医学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学 4 区 药学 4 区 核医学
JCR分区:
出版当年[2008]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q3 PHARMACOLOGY & PHARMACY Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q4 ONCOLOGY
最新[2023]版:
Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q3 ONCOLOGY Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2008版] 出版当年五年平均 出版前一年[2007版] 出版后一年[2009版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Dept Oncol, Tong Ji Hosp, TongJi Med Coll, Wuhan 430030, Peoples R China [*1]Huazhong Univ Sci & Technol, Dept Oncol, Tong Ji Hosp, TongJi Med Coll, Jiefang St 1095, Wuhan 430030, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Dept Oncol, Tong Ji Hosp, TongJi Med Coll, Wuhan 430030, Peoples R China [*1]Huazhong Univ Sci & Technol, Dept Oncol, Tong Ji Hosp, TongJi Med Coll, Jiefang St 1095, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:2 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)